In-silico guided identification and <i>in-vitro</i> studies of potential FFAR4 agonists for type 2 diabetes mellitus therapy
Comp35, diosmetin, CompN1, and CompN2 were found to be potential hit agonists and can be developed for therapy.
Authors
- Kiran Bharat Lokhande (ORCID: https://orcid.org/0000-0001-6945-8288)
- Aarti Sharma (ORCID: https://orcid.org/0000-0002-7186-6974)
- Pinky Juneja
- Gaurava Srivastava (ORCID: https://orcid.org/0000-0002-3996-5665)
- Divya Jhinjharia
- Shakti Sahi (ORCID: https://orcid.org/0000-0002-9931-7993)
- Savneet Kaur (ORCID: https://orcid.org/0000-0002-9863-2772)
- Jitendra Singh Rathore
Institutions
- Central Drug Research Institute (IN)
- Institute of Liver and Biliary Sciences (IN)
- Gautam Buddha University (IN)
Publication Details
- Journal
- Expert Opinion on Drug Discovery
- Published
- 2025-06-28
- DOI
- https://doi.org/10.1080/17460441.2025.2522896
- Citations
- 1
- Primary Topic
- Peroxisome Proliferator-Activated Receptors
- Type
- article
- Field-Weighted Citation Impact
- 0.81
Funders
- Indian Council of Medical Research